Pfizer To Become Largest Pharma In Japan After Wyeth Merger
This article was originally published in The Pink Sheet Daily
Together, the two pharmas’ domestic drug sales top Takeda’s reining 6.1 percent market share.
You may also be interested in...
Pfizer management, more bullish than the Street on long-term revenue forecasts for the combination of Pfizer and Wyeth, assured investors that incremental growth opportunities will emerge from the mega merger during a follow-up meeting with investors Jan. 27
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
MUMBAI - Pfizer's mega buyout of Wyeth for $68 billion is set to further strengthen the Indian businesses of the world's largest drug maker with additional focus on tapping the domestic formulations business and enhancing clinical trials